Trade war, CFIUS interventions force a shift in strategy at Fosun — signaling some big potential problems for US biotechs
Chinese biotech investors are getting caught in a big squeeze as President Donald Trump raises the stakes in an ongoing trade war with the Asian powerhouse. And the fallout could have major implications for a biotech industry that has become increasingly attuned to China’s ambitious group of deep-pocketed investors.
Kevin Xie, who manages Fosun International’s US strategy, tells Bloomberg that they’re turning greater attention to emerging markets as trade relations with the US grow increasingly frayed. Blacklisting Huawei Technologies has played a direct role in that shift.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.